Comparison of Novel Oral Anticoagulants and Warfarin in Elderly Patients With Nonvalvular Atrial Fibrillation
| Autor: | S G Kanorsky, V I Shevelev |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
medicine.medical_specialty
Rivaroxaban medicine.drug_mechanism_of_action business.industry Factor Xa Inhibitor Warfarin Atrial fibrillation medicine.disease Dabigatran Direct thrombin inhibitor Internal medicine Antithrombotic medicine Cardiology Apixaban cardiovascular diseases Cardiology and Cardiovascular Medicine business medicine.drug |
| Zdroj: | Scopus-Elsevier |
| ISSN: | 0022-9040 |
| DOI: | 10.18565/cardio.2015.10.58-63 |
| Popis: | We compared efficacy and safety of warfarin with those of direct thrombin inhibitor dabigatran, factor Xa inhibitors rivaroxaban and apixaban used for stroke prevention in 280 patients aged 65-80 years with non-valvular atrial fibrillation. Treatment for two years with dabigatran (110 mg twice daily), apixaban (5 mg twice daily) or rivaroxaban (20 mg/day) prevented strokes no less successfully than warfarin, but more rarely caused severe intracranial hemorrhages. When selecting antithrombotic therapy in geriatric patients with non-valvular AF new oral anticoagulants may be regarded as an acceptable alternative to warfarin. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|